Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis

Fig. 8

Mechanism of RT and YM101 combined therapy. Upper panels illustrate that schematic representation of the tumor microenvironment (TME) before and after treatment with RT and YM101. Combined RT and YM101 treatment induce multiple effects, including immune activation (increased DC maturation and pro-inflammatory cytokine/chemokine production), reduced T cell exhaustion, and enhanced T cell infiltration. Lower panels illustrate the impact of YM101 on radiation-induced pulmonary fibrosis (RIPF), demonstrating attenuated ECM deposition and fibrosis. The ability to attenuate RIPF while enhancing antitumor efficacy potentially broaden the therapeutic window for RT in the cancer treatment

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us